Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Solarboom 2024: Fünf Gründe, die für diese Aktie sprechen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
250 Leser
Artikel bewerten:
(0)

A Genetic Approach For Crohn's And Colitis Disease Is Financed By The Jeffrey Epstein VI Foundation

NEY YORK, July 3, 2012 /PRNewswire/ --The Jeffrey Epstein VI Foundation, which actively supports science research, has given substantial support to the Crohn's and Colitis Foundation of America to continue its Genetic Initiative to find a cure for the diseases.

Crohn's is a chronic inflammatory condition of the gastrointestinal tract. Every year, about 700,000 Americans are diagnosed, the majority being between the ages of 15 and 35. Crohn's affects the end of the small bowel, or ileum, the beginning of the colon and parts of the gastrointestinal tract. Ulcerative colitis affects the colon or large intestine.

The cause of Crohn's and Colitis is uncertain but the chronic inflammation stems from the immune system attacking microbial antigens in the gastrointestinal tract. Because of this, the disease is classified as an autoimmune disorder.

What is certain however is that Crohn's has a strong genetic component. Siblings are 30 times more likely to develop Crohn's than the general population. Children of those affected, are 3 to 20 times more likely to develop the disease and twins show a concordance of over 55%.

The Genetic Initiative at the Crohn's and Colitis Foundation of America, which recently received funding from The Jeffrey Epstein VI Foundation, is by far the most comprehensive effort of its kind to isolate the mutated genes that lead to the disease. The Initiative employs a dream team of specialists from different fields to identify genetic mutations and the chain of subsequent pathologies that cause Crohn's and Colitis. The Initiative is headed by Dr. Ramnik Xavier, Chairman of the Department of Gastroenterology at Massachusetts General Hospital in Boston. Xavier's laboratory has identified the largest number of genes associated with Crohn's to date. He is also a founding member of the Center for Computational and Integrative Biology.

The first mutation associated with Crohn's was the NOD2 gene (or CARD15) followed by the discovery of point mutations. Currently, more than thirty genetic mutations have been found, along with their consequences. Mutations of the XBP1 gene for example, directly affect the endoplasmatic reticulum's unfolded protein response pathway. The genetic mutation of ATG16L1 typically induces cell autophagy and can hinder the body's ability to attack invasive bacteria.

"As pluripotent stem cell technology improves, databases like the Genetic Initiative will be invaluable resources to curing such diseases as Crohn's and Colitis," Jeffrey Epstein remarks.

Founded in 1967, the Crohn's and Colitis Foundation of America is a non-profit organization dedicated to finding cures for Crohn's and ulcerative colitis. The Jeffrey Epstein VI Foundation was established in 2000 by science investor and financier, Jeffrey Epstein. Jeffrey Epstein has been an active supporter of genetic research, including the renowned Broad Institute which studies the entire human genome.

SOURCE www.jeffreyepstein.org

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.